NasdaqGS:BMRN

Stock Analysis Report

Executive Summary

BioMarin Pharmaceutical Inc., a biotechnology company, develops and commercializes therapies for people with serious and life-threatening rare diseases and medical conditions.


Snowflake Analysis

Excellent balance sheet with reasonable growth potential.


Similar Companies

Share Price & News

How has BioMarin Pharmaceutical's share price performed over time and what events caused price changes?


Latest Share Price and Events

Stable Share Price: BMRN has not had significant price volatility in the past 3 months.


Market Performance


7 Day Return

1.7%

BMRN

-2.5%

US Biotechs

-7.6%

US Market


1 Year Return

-2.2%

BMRN

8.9%

US Biotechs

10.2%

US Market

Return vs Industry: BMRN underperformed the US Biotechs industry which returned 6.5% over the past year.

Return vs Market: BMRN underperformed the US Market which returned 10.5% over the past year.


Shareholder returns

BMRNIndustryMarket
7 Day1.7%-2.5%-7.6%
30 Day6.2%2.8%-4.5%
90 Day13.0%2.2%-0.6%
1 Year-2.2%-2.2%9.8%8.9%12.5%10.2%
3 Year-2.4%-2.4%17.5%14.4%37.1%28.3%
5 Year-19.6%-19.6%-1.5%-6.0%60.8%43.2%

Price Volatility Vs. Market

How volatile is BioMarin Pharmaceutical's share price compared to the market and industry in the last 5 years?


Simply Wall St News

Valuation

Is BioMarin Pharmaceutical undervalued compared to its fair value and its price relative to the market?

19.2%

Undervalued compared to fair value


Share Price vs. Fair Value

Below Fair Value: BMRN ($91) is trading below our estimate of fair value ($112.77)

Significantly Below Fair Value: BMRN is trading below fair value, but not by a significant amount.


Price To Earnings Ratio

PE vs Industry: BMRN is unprofitable, so we can't compare its PE Ratio to the Biotechs industry average.

PE vs Market: BMRN is unprofitable, so we can't compare its PE Ratio to the US market.


Price to Earnings Growth Ratio

PEG Ratio: Insufficient data to calculate BMRN's PEG Ratio to determine if it is good value.


Price to Book Ratio

PB vs Industry: BMRN is overvalued based on its PB Ratio (5.3x) compared to the US Biotechs industry average (3x).


Next Steps

Future Growth

How is BioMarin Pharmaceutical forecast to perform in the next 1 to 3 years based on estimates from 24 analysts?

58.1%

Forecasted annual earnings growth


Earnings and Revenue Growth Forecasts


Analyst Future Growth Forecasts

Earnings vs Savings Rate: BMRN is forecast to become profitable over the next 3 years, which is considered faster growth than the savings rate (1.7%).

Earnings vs Market: BMRN is forecast to become profitable over the next 3 years, which is considered above average market growth.

High Growth Earnings: BMRN's is expected to become profitable in the next 3 years.

Revenue vs Market: BMRN's revenue (16.5% per year) is forecast to grow faster than the US market (7.6% per year).

High Growth Revenue: BMRN's revenue (16.5% per year) is forecast to grow slower than 20% per year.


Earnings per Share Growth Forecasts


Future Return on Equity

Future ROE: BMRN's Return on Equity is forecast to be low in 3 years time (17.3%).


Next Steps

Past Performance

How has BioMarin Pharmaceutical performed over the past 5 years?

15.0%

Historical annual earnings growth


Earnings and Revenue History

Quality Earnings: BMRN is currently unprofitable.

Growing Profit Margin: BMRN is currently unprofitable.


Past Earnings Growth Analysis

Earnings Trend: BMRN is unprofitable, but has reduced losses over the past 5 years at a rate of 15% per year.

Accelerating Growth: Unable to compare BMRN's earnings growth over the past year to its 5-year average as it is currently unprofitable

Earnings vs Industry: BMRN is unprofitable, making it difficult to compare its past year earnings growth to the Biotechs industry (66.2%).


Return on Equity

High ROE: BMRN has a negative Return on Equity (-1.38%), as it is currently unprofitable.


Next Steps

Financial Health

How is BioMarin Pharmaceutical's financial position?


Financial Position Analysis

Short Term Liabilities: BMRN's short term assets ($1.9B) exceed its short term liabilities ($493.7M).

Long Term Liabilities: BMRN's short term assets ($1.9B) exceed its long term liabilities ($990.0M).


Debt to Equity History and Analysis

Debt Level: BMRN's debt to equity ratio (27.4%) is considered satisfactory.

Reducing Debt: BMRN's debt to equity ratio has reduced from 43.5% to 27.4% over the past 5 years.


Balance Sheet

Inventory Level: BMRN has a high level of physical assets or inventory.

Debt Coverage by Assets: BMRN's debt is covered by short term assets (assets are 2.2x debt).


Cash Runway Analysis

For companies that have on average been loss making in the past we assess whether they have at least 1 year of cash runway.

Stable Cash Runway: BMRN has sufficient cash runway for more than 3 years based on its current free cash flow.

Forecast Cash Runway: Insufficient data to determine if BMRN has enough cash runway if its free cash flow continues to grow or shrink based on historical rates.


Next Steps

Dividend

What is BioMarin Pharmaceutical's current dividend yield, its reliability and sustainability?


Dividend Yield vs Market

Notable Dividend: Unable to evaluate BMRN's dividend yield against the bottom 25% of dividend payers, as the company has not reported any payouts.

High Dividend: Unable to evaluate BMRN's dividend yield against the top 25% of dividend payers, as the company has not reported any payouts.


Stability and Growth of Payments

Stable Dividend: Insufficient data to determine if BMRN's dividends per share have been stable in the past.

Growing Dividend: Insufficient data to determine if BMRN's dividend payments have been increasing.


Current Payout to Shareholders

Dividend Coverage: Insufficient data to calculate payout ratio to determine if its dividend payments are covered by earnings.


Future Payout to Shareholders

Future Dividend Coverage: No need to calculate the sustainability of BMRN's dividend in 3 years as they are not forecast to pay a notable one for the US market.


Next Steps

Management

How experienced are the management team and are they aligned to shareholders interests?

5.3yrs

Average management tenure


CEO

Jean-Jacques Bienaimé (66yo)

14.8yrs

Tenure

US$15,627,893

Compensation

Mr. Jean-Jacques Bienaime, MBA, has been the Chief Executive Officer of Biomarin Pharmaceutical Inc. since June 2005. He served as Director at Vital Therapies, Inc. since September 2013 to October 10, 2018 ...


CEO Compensation Analysis

Compensation vs Market: Jean-Jacques's total compensation ($USD15.63M) is above average for companies of similar size in the US market ($USD10.82M).

Compensation vs Earnings: Jean-Jacques's compensation has been consistent with company performance over the past year.


Leadership Team

NamePositionTenureCompensationOwnership
Jean-Jacques Bienaimé
Chairman & CEO14.8yrsUS$15.63m0.28% $46.4m
Robert Baffi
President of Global Manufacturing & Technical Operations0yrsUS$4.43m0.065% $10.7m
Jeffrey Ajer
Executive VP & Chief Commercial Officer7.3yrsUS$4.55m0.034% $5.6m
Henry Fuchs
President of Worldwide Research & Development3.3yrsUS$5.78m0.038% $6.2m
Daniel Spiegelman
Senior Advisor0.08yrsUS$4.52m0.0035% $580.0k
Brian Mueller
Senior VP of Finance0.08yrsno data0.011% $1.8m
Lon Cardon
Chief Scientific Strategy Officer0yrsno datano data
Traci McCarty
Vice President of Investor Relations0yrsno datano data
George Davis
Executive VP16.1yrsUS$2.71m0.038% $6.3m
Philip Scalzo
Senior VP & Chief Compliance Officer0yrsno datano data

5.3yrs

Average Tenure

60yo

Average Age

Experienced Management: BMRN's management team is seasoned and experienced (5.3 years average tenure).


Board Members

NamePositionTenureCompensationOwnership
Jean-Jacques Bienaimé
Chairman & CEO14.8yrsUS$15.63m0.28% $46.4m
Richard Meier
Lead Independent Director4.7yrsUS$544.66k0.042% $6.9m
Michael Grey
Independent Director14.2yrsUS$489.91k0.017% $2.7m
David E. Pyott
Independent Director4.1yrsUS$479.91k0.0076% $1.2m
Elaine Heron
Independent Director17.6yrsUS$500.66k0.024% $3.9m
Alan Lewis
Independent Director14.7yrsUS$489.91k0.0094% $1.5m
V. Lawlis
Independent Director12.7yrsUS$481.91k0.011% $1.7m
Willard Dere
Independent Director3.6yrsUS$478.66k0.0075% $1.2m
Dennis Slamon
Independent Director5.9yrsUS$478.66k0.0055% $901.2k
Robert Hombach
Independent Director2.4yrsUS$492.91k0.0018% $290.0k

5.3yrs

Average Tenure

66yo

Average Age

Experienced Board: BMRN's board of directors are considered experienced (5.3 years average tenure).


Ownership

Who are the major shareholders and have insiders been buying or selling?


Insider Trading Volume

Insider Buying: Insufficient data to determine if insiders have bought more shares than they have sold in the past 3 months.


Ownership Breakdown

Dilution of Shares: Shareholders have not been meaningfully diluted in the past year.


Top Shareholders

Company Information

BioMarin Pharmaceutical Inc.'s company bio, employee growth, exchange listings and data sources


Key Information

  • Name: BioMarin Pharmaceutical Inc.
  • Ticker: BMRN
  • Exchange: NasdaqGS
  • Founded: 1996
  • Industry: Biotechnology
  • Sector: Pharmaceuticals & Biotech
  • Market Cap: US$16.385b
  • Shares outstanding: 179.63m
  • Website: https://www.biomarin.com

Number of Employees


Location

  • BioMarin Pharmaceutical Inc.
  • 770 Lindaro Street
  • San Rafael
  • California
  • 94901
  • United States

Listings

TickerExchangePrimary SecuritySecurity TypeCountryCurrencyListed on
BMRNNasdaqGS (Nasdaq Global Select)YesCommon StockUSUSDJul 1999
BM8DB (Deutsche Boerse AG)YesCommon StockDEEURJul 1999
BMRNWBAG (Wiener Boerse AG)YesCommon StockATEURJul 1999
0HNCLSE (London Stock Exchange)YesCommon StockGBUSDJul 1999
BM8ETLX (Eurotlx)YesCommon StockITEURJul 1999
BMRN *BMV (Bolsa Mexicana de Valores)YesCommon StockMXMXNJul 1999
B1MR34BOVESPA (Bolsa de Valores de Sao Paulo)BDR EACH 2 REPR 1 COMBRBRLJan 2020

Biography

BioMarin Pharmaceutical Inc., a biotechnology company, develops and commercializes therapies for people with serious and life-threatening rare diseases and medical conditions. Its commercial products include Aldurazyme to treat mucopolysaccharidosis I, a genetic disease; Brineura for the treatment of late infantile neuronal ceroid lipofuscinosis type 2, a form of Batten disease; and Kuvan, a proprietary synthetic oral form of 6R-BH4 that is used to treat patients with phenylketonuria (PKU), an inherited metabolic disease. The company’s commercial products also comprise Naglazyme, a recombinant form of N-acetylgalactosamine 4-sulfatase for patients with mucopolysaccharidosis VI; Palynziq, a PEGylated recombinant phenylalanine ammonia lyase enzyme for adult patients with PKU; Vimizim, an enzyme replacement therapy for the treatment of mucopolysaccharidosis IV Type A, a lysosomal storage disorder; and Firdapse for lambert eaton myasthenic syndrome. Its clinical and pre-clinical product pipeline includes valoctocogene roxaparvovec, an adeno associated virus vector drug development candidate in patients with severe hemophilia A; and vosoritide, a peptide therapeutic for the treatment of achondroplasia, a form of disproportionate short stature in humans. The company serves specialty pharmacies; and end-users, such as hospitals and foreign government agencies, as well as distributors and pharmaceutical wholesalers in the United States, Europe, Latin America, and internationally. It has collaboration and license agreements with Sarepta Therapeutics and Asubio Pharma Co., Ltd. The company was founded in 1996 and is headquartered in San Rafael, California. 


Company Analysis and Financial Data Status

All financial data provided by Standard & Poor's Capital IQ.
DataLast Updated (UTC time)
Company Analysis2020/02/27 00:43
End of Day Share Price2020/02/26 00:00
Earnings2019/09/30
Annual Earnings2018/12/31


Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.